Compare DARE & BHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DARE | BHM |
|---|---|---|
| Founded | 2015 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4M | 40.1M |
| IPO Year | 2014 | 2022 |
| Metric | DARE | BHM |
|---|---|---|
| Price | $2.11 | $10.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $10.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 228.4K | 5.2K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,807,885.00 | ★ $68,734,000.00 |
| Revenue This Year | $2,115.12 | N/A |
| Revenue Next Year | $122.62 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.88 |
| 52 Week Low | $1.27 | $8.05 |
| 52 Week High | $9.19 | $14.81 |
| Indicator | DARE | BHM |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 42.27 |
| Support Level | $1.94 | $8.46 |
| Resistance Level | $2.01 | $9.67 |
| Average True Range (ATR) | 0.15 | 0.54 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 29.79 | 33.33 |
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The company has two reportable segments, consisting of Residential Communities, which derives maximum revenue; and Scattered Single-family homes.